{"product_id":"transparency-power-and-influence-in-the-pharmaceutical-industry-policy-gain-or-confidence-game-paperback-softback-9781487529048","title":"Transparency, Power, and Influence in the Pharmaceutical Industry; Policy Gain or Confidence Game? (Paperback \/ softback) 9781487529048","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eTransparency, Power, and Influence in the Pharmaceutical Industry\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003ePolicy Gain or Confidence Game?\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eKatherine Fierlbeck (Edited by), Janice Graham (Edited by), Matthew Herder (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781487529048\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003ePaperback \/ softback, published 14 June 2021\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e304 pages, 1 figure\u003cbr\u003e22.9 x 15.2 x 1.9 cm, 0.38 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eThere is plenty of controversy surrounding pharmaceuticals, but it cannot be denied that the pharmaceutical industry is both socially beneficial and profitable. Regulators are expected to ensure that the economic success of the industry does not come at the expense of public safety, yet they have also assumed a cooperative role by providing advice on regulation and by targeting unmet medical needs. Concerns over regulatory standards, conflicts of interest, and the manipulation of information on drug safety and effectiveness have led to public mistrust and a greater need for transparency between the pharmaceutical industry and government regulators.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eTransparency, Power, and Influence in the Pharmaceutical Industry\u003c\/i\u003e evaluates the progress made in holding the pharmaceutical industry responsible for creating transparency in the industry, from development to market. The contributors to this volume examine the various mechanisms introduced to make the regulatory process more informative and situate these efforts within the larger project of enhancing the safety of drugs, vaccines, and other products.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e1. Introduction\u003cbr\u003eKatherine Fierlbeck, Janice Graham, and Matthew Herder\u003c\/p\u003e \u003cp\u003e2. Transparency, Pharmaceuticals, and the Problem of Policy Change\u003cbr\u003eKatherine Fierlbeck \u003c\/p\u003e \u003cp\u003e3. Data Transparency and Pharmaceutical Regulation in Europe: Road to Damascus, or Room without a View?\u003cbr\u003eCourtney Davis, Shai Mulinari, and Tom Jefferson\u003c\/p\u003e \u003cp\u003e4. FDA and Health Canada: Similar Origins, yet Divergent Paths and Approaches to Transparency\u003cbr\u003eMargaret McCarthy and Joe Ross \u003c\/p\u003e \u003cp\u003e5. Clinical Trial Data Transparency in Canada: Mapping the Progress from Laggard to Leader\u003cbr\u003eMarc-André Gagnon, Matthew Herder, Janice Graham, Katherine Fierlbeck, and Anna Danyliuk \u003c\/p\u003e \u003cp\u003e6. How Clinical Study Information Transparency Can Fail to Serve Its Purpose, and How the Essential Medicines Concept Can Help\u003cbr\u003eNav Persaud \u003c\/p\u003e \u003cp\u003e7. Speak No Secrets: (Non)transparency in Health Canada\u0026amp;#x2019;s Communications about Pharmaceutical Regulation\u003cbr\u003eJoel Lexchin \u003c\/p\u003e \u003cp\u003e8. Economic Ghost-Management in the Pharmaceutical Sector\u003cbr\u003eMarc-Andre Gagnon \u003c\/p\u003e \u003cp\u003e9. Balancing the Privacy Rights of Research Participants with the Public Interest in Clinical Drug Trials Data in the Context of Rare Diseases\u003cbr\u003eKanksha Mahadevia Ghimire and Trudo Lemmens \u003c\/p\u003e \u003cp\u003e10. The European Registration of the Pandemic Influenza Vaccine Pandemrix: A Case Study of the Consequences of Poor Clinical Data Transparency\u003cbr\u003eTom Jefferson \u003c\/p\u003e \u003cp\u003e11. Sharing Data and Ideas for Good Health: How Researchers Can Sustain an Ethical and Transparent Health System \u003cbr\u003eRita Banzi \u003c\/p\u003e \u003cp\u003e12. Conclusion\u003cbr\u003eKatherine Fierlbeck, Janice Graham, and Matthew Herder\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003c\/font\u003e","brand":"University of Toronto Press","offers":[{"title":"Brand New","offer_id":52739656974616,"sku":"9781487529048","price":20.86,"currency_code":"GBP","in_stock":true}],"url":"https:\/\/freshlyprintedbooks.co.uk\/products\/transparency-power-and-influence-in-the-pharmaceutical-industry-policy-gain-or-confidence-game-paperback-softback-9781487529048","provider":"Freshly Printed Books","version":"1.0","type":"link"}